Drug profile

The FDA adverse-event record for Imrab 3

17 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Imrab 3. See the species affected, top reactions, and outcomes below.

17
adverse-event reports
5.9%
death-coded share
Dog
most-reported species
6
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
17
Total Reports
1
Deaths Reported
5.9%
Death Rate

Active Ingredients

Imrab 3

Administration Routes

UnknownSubcutaneousIntramuscular

Species Affected

Dog 15
Horse 1
Cattle 1

Most Affected Breeds

Shepherd Dog - German 3
Terrier - Bull - American Pit 2
Pug 2
Bulldog 1
Terrier - Yorkshire 1
Chihuahua 1
Mustang 1
Bichon Frise 1
Dachshund (unspecified) 1
Guernsey 1

Most Reported Reactions

Vomiting 6
Lethargy (see also Central nervous system depression in 'Neurological') 4
Lethargy (see also Central nervous system depression in Neurological) 4
Facial swelling (see also Skin) 4
Diarrhoea 3
Not eating 2
Anaphylaxis 2
Hives (see also 'Skin') 1
Swelling NOS 1
Allergic reaction 1
Shivering 1
Vocalisation 1

Outcome Breakdown

Recovered/Normal
8 (47.1%)
Ongoing
6 (35.3%)
Outcome Unknown
2 (11.8%)
Died
1 (5.9%)

Imrab 3 Adverse Event Insights

17 reports name Imrab 3; 1 recorded a death outcome (5.9% of reported events, not a population-level mortality rate). Active ingredient: Imrab 3. Administration routes: Unknown, Subcutaneous, Intramuscular.

By species: Dog (15 reports), Horse (1 reports), Cattle (1 reports). By breed: Shepherd Dog - German (3), Terrier - Bull - American Pit (2), Pug (2).

Leading clinical signs: Vomiting (6), Lethargy (see also Central nervous system depression in 'Neurological') (4), Lethargy (see also Central nervous system depression in Neurological) (4), Facial swelling (see also Skin) (4). Outcome, 17 coded reports: Recovered/Normal leads at 47.1%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.